A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients
| Autor: | Thierry Maisonobe, Karine Viala, Corina Cret, Samir Saheb, Sophie Demeret, Pauline Reach, Rabab Debs |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Clinical state Chronic inflammatory demyelinating polyneuropathy Gastroenterology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Conduction abnormalities Dose-Response Relationship Drug biology Maintenance dose Treatment regimen business.industry General Neuroscience Immunoglobulins Intravenous General Medicine Middle Aged medicine.disease Treatment management Treatment Outcome 030104 developmental biology Polyradiculoneuropathy Chronic Inflammatory Demyelinating Intravenous Immunoglobulins Immunology biology.protein Female Antibody business 030217 neurology & neurosurgery |
| Zdroj: | International Journal of Neuroscience. 127:864-872 |
| ISSN: | 1543-5245 0020-7454 |
| DOI: | 10.1080/00207454.2016.1269328 |
| Popis: | Chronic inflammatory demyelinating polyneuropathy (CIDP) is treated with intravenous immunoglobulins (IVIg), corticosteroids or plasma exchange (PE). IVIg dosage is not universal and markers for treatment management are needed.We report the response to high-dose and fractioned IVIg in a subgroup of definite CIDP patients, resistant to corticosteroids and PE, responders to IVIg but with an efficacy window15 d.Four patients were included with similar predominantly clinical motor form and conduction abnormalities. Treatment management consisted of fractioning IVIg and increasing the monthly cumulated dose (mean: 3 g/kg/month). Serum IgG concentration was measured and correlated to the clinical state. Monitoring of serum IgG helped to guide IVIg administration dosage and frequency. A mean of 10 months was required to improve symptoms; therapy was then switched to subcutaneous (SC) route (maintenance dose: 3.5 g/kg/month). The mean Overall Neuropathy Limitations Scale was improved from 11 to 3.2 and the mean Medical Research Council scale from 26 to 90.It is important to distinguish patients with short IVIg efficacy window from those with classical resistance since the former may benefit from fractioning and increasing the IVIg dose. The monitoring of serum IgG level and its correlation to the clinical response could be of help in monitoring each individual's dosage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|